BiotechTube

Abatacept

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Juvenile Idiopathic Arthritis

Conditions

Juvenile Idiopathic Arthritis

Trial Timeline

Aug 9, 2013 → Jul 30, 2018

NCT ID
NCT01835470

About Abatacept

Abatacept is a phase 3 stage product being developed by Ono Pharmaceutical for Juvenile Idiopathic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT01835470. Target conditions include Juvenile Idiopathic Arthritis.

What happened to similar drugs?

0 of 20 similar drugs in Juvenile Idiopathic Arthritis were approved

Approved (0) Terminated (2) Active (18)
🔄PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
🔄AdalimumabEisaiPhase 3
🔄Ixekizumab + AdalimumabEli LillyPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01835470Phase 3Completed

Competing Products

20 competing products in Juvenile Idiopathic Arthritis

See all competitors
ProductCompanyStageHype Score
PLX-200 + PlaceboPolaryx TherapeuticsPhase 3
37
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab) + placeboChugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
MRA(Tocilizumab)Chugai PharmaceuticalPhase 3
40
AdalimumabEisaiPhase 3
40
Ixekizumab + AdalimumabEli LillyPhase 3
44
Baricitinib + PlaceboEli LillyPhase 3
40
BaricitinibEli LillyPhase 3
47
Baricitinib + TocilizumabEli LillyPhase 3
47
adalimumab + MethotrexateAbbViePre-clinical
26
UpadacitinibAbbViePhase 1
33
Upadacitinib + TocilizumabAbbViePhase 3
47
Adalimumab + RisankizumabAbbViePhase 3
47
AdalimumabAbbViePhase 3
40
naproxen + esomeprazoleAstraZenecaPhase 1
29
Alendronate (Fosamax)MerckPre-clinical
26
canakinumabNovartisPhase 3
40
SecukinumabNovartisPhase 1
36
ACZ885 150 mg (Canakinumab)NovartisPhase 3
40